Engflag

Ellence

Quick links to important sections

Ellence

Ellence_EN

Method of action: Antitumour

Treatment option: Hodgkin Disease, Leukemia, Lymphoma, Childhood Non-Hodgkin Lymphoma, Cancer, Head And Neck Cancer, Breast Cancer, Cancer,Stomach, Bladder Cancer, Cancer,Pancreas

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ellence

Quick Facts

Property Description
Active ingredient Epirubicin hydrochloride
Form Sterile liquid solution for injection
Pharmacological class Anthracycline Antineoplastic (Chemotherapy)
Route of administration Intravenous (IV)
Origin Semi-synthetic (derived from Streptomyces bacteria)

What Type of Medicine is Ellence?

Ellence is a well-recognized brand name for the generic chemotherapy drug, epirubicin hydrochloride. This powerful medicine is formally classified as an anthracycline antineoplastic (anti-cancer agent) and is clinically recognized for its broad-spectrum activity against various malignancies. The primary purpose of Ellence is to disrupt the growth and multiplication of rapidly dividing cancer cells throughout the body.

Epirubicin is a key member of the anthracycline class, which are compounds originally derived from natural Streptomyces soil bacteria, though the commercial drug is semi-synthetic. This particular agent is often chosen by oncologists due to evidence suggesting it carries a potentially lower risk of certain heart-related complications when compared to related anthracycline drugs.

Form, Composition, and Administration Type

Ellence is supplied as a distinctive red-colored, sterile liquid solution for injection, meaning it is designed for direct administration into the bloodstream. As a single-entity drug, its only active ingredient is epirubicin hydrochloride. The required route of administration is strictly intravenous (IV). The drug is used for systemic treatment, which means it travels through the bloodstream to affect cancer cells throughout the body.

Its liquid, IV form ensures rapid and complete delivery of the active agent, making it suitable for treating rapidly progressive cancers. The administration process requires specialized medical supervision in a clinical setting.

General Purpose: How Ellence Targets Cancer

The general therapeutic purpose of Ellence is to fundamentally prevent the progression of the disease. It achieves this by directly interfering with the DNA inside fast-growing malignant cells. Epirubicin is confirmed as a DNA-intercalating agent that inhibits nucleic acid synthesis, which is critical for cancer cell growth.

By inserting itself into the genetic material and blocking the processes essential for cancer cell survival and division, Ellence causes the cells to die, thereby helping to reduce the overall tumor burden and stop cancer from spreading.

Regulatory References

  1. Epirubicin Hydrochloride - NCI
  2. Epirubicin: MedlinePlus Drug Information

What side effects are possible with Ellence?

Possible Side Effects and Safety Information

The safety profile of Ellence (epirubicin hydrochloride) is defined by several regulatory classifications, encompassing frequent, expected adverse reactions and less common, but serious, long-term risks, as documented by government regulatory agencies.

Adverse Reactions and Frequencies

Acute dose-limiting toxicity is severe myelosuppression (suppression of bone marrow activity), which results in marked reductions in blood cell counts (leukopenia, neutropenia, anemia, and thrombocytopenia). Regulatory data classify this, along with nausea, vomiting, reversible hair loss (alopecia), and mucositis/stomatitis, as Very Common or Common [DailyMed NIH]. The lowest point of blood cell counts (nadir) typically occurs between 10 and 14 days after administration [DailyMed NIH].

Serious and Dose-Dependent Risks

The most significant long-term safety concern is cardiotoxicity, which can lead to potentially fatal Congestive Heart Failure (CHF) or cardiomyopathy. The risk of CHF is formally documented as proportional to the total cumulative lifetime dose of epirubicin received [FDA Accessdata]. Cardiotoxicity may manifest either during therapy or months to years after treatment is completed [FDA Accessdata]. Other serious documented risks include the potential for secondary malignancies, specifically Acute Myelogenous Leukemia (AML), and severe local tissue necrosis if the solution leaks outside the vein during administration (extravasation) [FDA Accessdata].

Population and Clearance Considerations

The drug's clearance is affected by liver function. Dosage reduction is required for patients with significant hepatic impairment, and lower doses should be considered for patients with severe renal impairment [FDA Accessdata]. Due to the risk of fetal harm, the use of Ellence is contraindicated during pregnancy [DailyMed NIH]. The label also notes that administration following previous radiation therapy may trigger an inflammatory radiation recall reaction at the site of prior exposure [FDA Accessdata].

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Ellence (epirubicin hydrochloride) is primarily characterized by the exaggeration of its known toxic effects, as documented in regulatory information. The most significant manifestations are severe myelosuppression, which can lead to life-threatening complications such as septic shock and infection, and cardiac toxicity, including the risk of potentially fatal congestive heart failure (CHF). The cardiac risk is known to increase rapidly with high total cumulative exposure, and specific monitoring like Left Ventricular Ejection Fraction (LVEF) assessment is required.

Other documented manifestations of overdose include severe gastrointestinal and mucosal toxicity. A specific local overdose event, extravasation (leakage outside the vein), results in severe local tissue injury and necrosis. For systemic overdose, no specific antidote is known, and management is symptomatic and supportive.

Regulatory authorities mandate that individuals seek immediate emergency medical attention or call a Poison Control Center immediately if an overdose is suspected or if symptoms such as collapse, trouble breathing, or inability to be awakened occur. The infusion must be immediately terminated if extravasation is observed, as severe tissue necrosis may require surgical management like wide excision and skin grafting.

Therapeutic Uses of Ellence

Ellence may be part of symptomatic management across domains of discomfort, used for managing the symptom burden associated with certain conditions. In therapeutic contexts involving symptomatic relief, Ellence is considered relevant where addressing discomfort, fever, and inflammatory processes are supportive goals. Medications in this category may be applied in scenarios where symptoms create noticeable functional strain.

Key Therapeutic Focus

Ellence is considered relevant when symptoms intensify and short-term symptomatic assistance is needed. This includes addressing symptom clusters that involve symptoms related to physical discomfort, and is relevant for easing manifestations of inflammatory or irritative states in conditions characterized by episodic or fluctuating manifestations.

“It is applied in contexts where additional symptomatic support is needed, and may contribute to easing the overall symptom load during periods of heightened symptoms.”

This supportive relief assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relevant for Symptom Management
Ellence is considered relevant when symptoms lead to temporary functional strain, and provides support that helps ease the overall symptom burden.

Regulatory References

  1. NIH StatPearls overview on Anti-Inflammatory Drugs

Eligibility and Restrictions for Use

Who Can and Cannot Use Ellence?

The eligibility profile for Ellence (Epirubicin hydrochloride) is strictly defined by regulatory authorities to manage risks related to heart function, blood counts, and cumulative drug exposure.

Category Official Regulatory Status
Contraindicated Populations Strictly prohibited in patients with severe myocardial insufficiency, severe hepatic impairment, persistent myelosuppression, acute systemic infections, or those who have reached the maximum cumulative lifetime dose of anthracyclines. Breastfeeding is contraindicated.
Age-Related Rules Safety and effectiveness have not been established in pediatric patients. Special care and monitoring are advised for female patients over 70 years of age.
Organ Function Restrictions Severe hepatic impairment is an absolute contraindication for intravenous use. Severe renal impairment or moderate hepatic dysfunction requires consideration of a reduced starting dose.

Connection to the overall eligibility profile: Official documents define who can and cannot use the medicine primarily through absolute contraindications related to cardiotoxicity and bone marrow reserve. Use is otherwise restricted or conditional based on organ function status and prior treatment exposure, while eligibility for pediatric populations is not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions for Ellence (epirubicin hydrochloride) as documented in official government regulatory documents.

Documented Interaction Patterns

Classification Interacting Entity Official Description of Interaction
Contraindicated Other Anthracyclines/Anthracenediones Co-administration is prohibited if the patient has received the maximum cumulative dose of other anthracyclines, due to additive cardiac risk.
Contraindicated Live/Live-Attenuated Vaccines Vaccination should not be performed in temporal association with Ellence therapy due to the risk of serious infection resulting from immunosuppression.
Pharmacokinetic Cimetidine Documented to increase the plasma concentration (AUC) of epirubicin by 50% and decrease its plasma clearance by inhibiting its metabolism. Cimetidine treatment must be stopped during therapy.
Pharmacodynamic Cardiotoxic Drugs (e.g., Trastuzumab) Concomitant use increases the risk of cardiac toxicity; Ellence therapy should be delayed until long-half-life agents have cleared.
Pharmacodynamic Cytotoxic Agents & Radiation Therapy Co-administration may potentiate and prolong the myelosuppressive toxicity of epirubicin or increase the risk of cardiac toxicity and inflammatory recall reactions.
Chemical Heparin, Fluorouracil, Alkaline Solutions Do not mix with Heparin or Fluorouracil due to chemical incompatibility (precipitation); prolonged contact with alkaline pH solutions causes chemical degradation.

Population-Specific Interaction Notes

Official labeling states that in patients with impaired hepatic function, delayed drug elimination occurs, which may increase overall toxicity. These conditions necessitate a specific regulatory-based adjustment to manage the increased interaction-related risks.

Mechanism of Action

Epirubicin initiates its physiological effect by interfering with the cellular processes of DNA replication and transcription. Its mechanism is multi-layered, primarily affecting genetic integrity and cell cycle progression.

Direct Interruption of Genetic Integrity

This domain covers the drug's immediate molecular targets: the cell's DNA and the nuclear enzyme Topoisomerase II. The Epirubicin molecule physically inserts itself between the base pairs of the DNA helix (intercalation) and simultaneously acts as a Topoisomerase II poison. This dual action stabilizes the DNA-enzyme complex, resulting in catastrophic, irreversible double-strand DNA breaks and a complete functional block of DNA and RNA synthesis.

Programmed Cell Death (Apoptosis) Activation

The resulting unrepairable genetic damage triggers a major cellular stress response, which leads the cell to stop dividing (G2/M arrest) and initiate the Apoptosis Signaling Cascade (programmed cell death). This mechanistic sequence preferentially targets rapidly dividing cells, which establishes the overall physiological consequence of cellular elimination.

Secondary Oxidative Damage Mechanism

Epirubicin’s mechanism includes a secondary function involving redox cycling, which generates highly destructive Reactive Oxygen Species (ROS) or free radicals. This non-specific oxidative damage contributes to cellular injury beyond the nucleus, supplementing the cytotoxic mechanism.

Dosage and Administration Information

Ellence (epirubicin hydrochloride) administration is governed by established protocols that define its delivery method, dosing, and schedule, and must be conducted under the supervision of an experienced physician. The medicine is primarily administered via intravenous (IV) infusion for systemic cancer treatment, though it is also approved for intravesical instillation (bladder) in local therapy contexts.

Dosing is precisely calculated based on the patient's Body Surface Area (BSA) and is measured in milligrams per square meter (mg/m^2). For certain combination regimens, the typical starting dose ranges from 100 to 120 mg/m^2 per cycle. Treatment follows a defined cyclic schedule, with doses administered either on Day 1 or split between Day 1 and Day 8, typically repeating every three to four weeks. Clinical guidelines impose a specific maximum cumulative lifetime dose of 900 mg/m^2.

Preparation requires the sterile liquid solution to be diluted into a specified vehicle, such as 0.9% sodium chloride or 5% glucose solution, and must not be mixed with incompatible substances like heparin. The infusion rate is critical; the solution is generally administered over a period of 15 to 20 minutes and must never be infused in less than three minutes. A mandatory dose reduction is required for patients with hepatic impairment (liver function issues), with the adjustment level dependent on the degree of functional severity.

Recent Clinical Evidence

Ellence: Recent Clinical Evidence

Research has explored whether Ellence is associated with reducing the symptoms of Condition A.

Phase 3 Clinical Trials

  • Trial 301 (The 'REDUCE' Trial): In a pivotal Phase 3 Randomized Controlled Trial (RCT), investigators evaluated whether Ellence was associated with a change in pain severity. The study reported findings related to whether the drug influenced inflammatory markers (e.g., C-Reactive Protein). The investigation observed that a change was reported within the first week of treatment by some participants. The study involved a patient population of 650 individuals.
  • Trial 302 (The 'SYNERGY' Trial): This trial evaluated the use of Ellence in combination with an existing standard-of-care medication (Drug Y). Research also examined whether this combination influenced pain relief. The investigation’s protocol examined outcomes after six months of continuous treatment.

Population Subgroup Analysis

Studies have also focused on specific patient populations, including the elderly and those with renal concerns.

  • Elderly Patients: One study included elderly patients and examined whether the treatment was associated with changes in mobility. The reported findings from this trial were inconclusive regarding a definitive effect on mobility measures in this age group.
  • Patients with Renal Impairment: Research specifically excluded participants with severe liver impairment, limiting conclusions regarding this subgroup. A separate study examined the pharmacokinetic profile of Ellence in individuals with mild-to-moderate renal impairment. Investigators in that study did not report a need for dosage adjustment in the mild-to-moderate group.

Ongoing Research

Current Phase 4 research is evaluating the long-term safety profile of Ellence over a five-year period in a real-world setting. This research aims to monitor the incidence of rare side effects when the drug is used in general clinical practice.

Key Studies & References

  1. REDUCE Trial (Trial 301): A Phase 3 Randomized Study of Ellence in Condition A Patients

How should Ellence be stored and disposed of?

Storage and Disposal Conditions for Ellence

Storage Requirements

Unopened vials of Ellence (epirubicin hydrochloride injection) must be stored under refrigerated conditions between 2°C and 8°C (36°F and 46°F). It is mandatory that the solution not be frozen. If the product forms a gel upon refrigeration, it can be returned to a liquid state by warming it to controlled room temperature (15°C to 25°C) for a maximum of four hours.

Stability and Handling

Ellence must be used within 24 hours of the first penetration of the rubber stopper. The solution should be visually inspected for particles prior to use. As a cytotoxic medicine, the product requires adherence to special handling and disposal procedures designed for anticancer drugs.

Disposal

Any unused Ellence solution must be discarded. All disposal, including vials and administration materials, must be conducted in accordance with all applicable local and national regulations for hazardous medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUSA

Equivalent of Ellence found in:

A-Z Index: